HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Mar 2017 07:00 AM
RNS
Positive Fruquintinib Pivotal Phase III Results
28 Feb 2017 10:20 AM
RNS
Change of Directors
20 Feb 2017 07:00 AM
RNS
Start of Phase II Savolitinib PSC trial in China
14 Feb 2017 07:07 AM
RNS
Initiates Phase I of Novel FGFR Inhibitor HMPL-453
14 Feb 2017 07:00 AM
RNS
Savolitinib PRCC Results Presentation at ASCO GU
06 Feb 2017 07:00 AM
RNS
Chi-Med to Announce 2016 Final Results
01 Feb 2017 07:00 AM
RNS
Change of Directors
16 Jan 2017 10:48 AM
RNS
Change of Directors
16 Jan 2017 10:11 AM
RNS
Change of Directors
16 Jan 2017 07:30 AM
RNS
Fruquintinib Phase I/II Clinical Data at ASCO GI
16 Jan 2017 07:29 AM
RNS
Sulfatinib Phase II Study in 2nd Line BTC in China
16 Jan 2017 07:16 AM
RNS
Fruquintinib Combination Study in 1st-Line NSCLC
10 Jan 2017 07:00 AM
RNS
Chi-Med Initiates HMPL-523 Clinical Trials
30 Dec 2016 09:11 AM
RNS
Total Voting Rights
29 Dec 2016 07:40 AM
RNS
Blocklisting Six Monthly Return
20 Dec 2016 07:18 AM
RNS
Director's Share Dealing
14 Dec 2016 07:14 AM
RNS
Director's Share Dealing
06 Dec 2016 07:00 AM
RNS
HMPL-523 Pre-clinical Data Presented at ASH
30 Nov 2016 07:51 AM
RNS
Exercise of Share Options
30 Nov 2016 07:48 AM
RNS
Total Voting Rights
23 Nov 2016 07:34 AM
RNS
Director's Share Dealing
23 Nov 2016 07:30 AM
RNS
Chi-Med to Present Data at the 17th WCLC
23 Nov 2016 07:08 AM
RNS
Chi-Med to Present Data at the at the 17th WCLC
14 Nov 2016 09:06 AM
RNS
Chi-Med Presents Ph I Clinical Data for HMPL-523
01 Nov 2016 02:57 PM
RNS
Director's Share Dealing
31 Oct 2016 07:00 AM
RNS
Joint Venture - US$59.5m Land Compensation Payment
12 Oct 2016 07:00 AM
RNS
Director's Share Dealing
09 Aug 2016 08:07 AM
RNS
Director's Share Dealing
02 Aug 2016 08:18 AM
RNS
Change of Non-executive Directors
02 Aug 2016 07:00 AM
RNS
Chi-Med 2016 Interim Results
01 Aug 2016 07:21 AM
RNS
Chi-Med and AstraZeneca to Accelerate Savolitinib
05 Jul 2016 07:00 AM
RNS
Chi-Med to Announce 2016 HY Financial Results
29 Jun 2016 07:00 AM
RNS
Blocklisting Six Monthly Return
20 Jun 2016 07:00 AM
RNS
Savolitinib Global Phase II Trial Initiated
15 Jun 2016 08:09 AM
RNS
Additional Listing
31 May 2016 07:00 AM
RNS
Total Voting Rights
13 May 2016 07:00 AM
RNS
Enrollment completion of Phase III fruquintinib
29 Apr 2016 07:00 AM
RNS
Total Voting Rights
27 Apr 2016 01:12 PM
RNS
Results of Annual General Meeting
13 Apr 2016 04:23 PM
RNS
Exercise of Overallotment Option
12 Apr 2016 07:00 AM
RNS
Clinical trial of novel PI3K inhibitor HMPL-689
31 Mar 2016 07:00 AM
RNS
Total Voting Rights
29 Mar 2016 08:00 AM
RNS
Director/PDMR Shareholding
23 Mar 2016 10:34 AM
RNS
Holding(s) in Company
22 Mar 2016 02:00 PM
RNS
Closing of U.S. Public Offering of ADSs
21 Mar 2016 08:54 AM
RNS
Director/PDMR Shareholding
21 Mar 2016 07:00 AM
RNS
Sulfatinib Phase III registration study
18 Mar 2016 04:18 PM
RNS
Final Prospectus
17 Mar 2016 07:00 AM
RNS
Pricing of U.S. Public Offering of ADSs
15 Mar 2016 07:00 AM
RNS
2015 Annual Report and Notice of AGM

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100